LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 504

Search options

  1. Book ; Online ; E-Book: Targeting oncogenic drivers and signaling pathways in lymphoid malignancies

    O'Connor, Owen A. / Ansell, Stephen M. / Seymour, John

    from concept to practice

    (Precision cancer therapies ; Volume 1)

    2023  

    Abstract: If one asks a cancer scientist a seemingly naive question such as what are the hallmarks of cancer cells, he-she will probably cite at first somatic mutations and genomic rearrangement, leading to excessive proliferation, resistance to apoptosis, and ... ...

    Author's details edited by Owen A. O'Connor, Stephen Ansell, and John Seymour
    Series title Precision cancer therapies ; Volume 1
    Abstract "If one asks a cancer scientist a seemingly naive question such as what are the hallmarks of cancer cells, he-she will probably cite at first somatic mutations and genomic rearrangement, leading to excessive proliferation, resistance to apoptosis, and dissemination potential (Hanahan and Weinberg, 2011). Intriguingly, all of these hallmarks are physiological properties of B- and T-lymphocytes, selected by evolution because they ensure an efficient immune response against pathogens. So, it is a fascinating paradox to observe that lymphoma remains a relatively rare cancer as compared to epithelial cancers. Hence, understanding the tumor suppressor mechanisms that mitigate lymphomagenesis or eradicate lymphoma cells at preclinical stages appears an extraordinary challenge. After a short overview of the current models used to analyze lymphomagenesis, we will highlight that the frontier between reactive lymphoproliferation and overt lymphoma is not always clear. Then, we will present how the classification of lymphomas based on the concept of cell of origin might reveal important phenotypical properties of lymphoma subtypes. Finally, we propose an overview of the main hallmarks of lymphomas and discuss their contribution in the most frequent subtypes of lymphomas. How to study lymphomagenesis As in other scientific fields, the nature of our knowledge of lymphomagenesis is tightly linked to the tools used to produce this knowledge. Hence, it seems interesting to start this review with a methodological perspective, providing a brief overview of the different scientific approaches which have brought major contributions to our understanding of lymphomagenesis. Epidemiology was the first approach which shed light on the mechanisms of lymphomagenesis, by deriving statistical correlations from direct observation of cohorts of patients. First, epidemiology has established the link between lymphoma incidence and aging. The incidence of most lymphomas follows an exponential growth after the fifth decade as observed for most cancers, suggesting that common processes are shared with solid tumors (Sarkozy et al., 2015; Rozhok and DeGregori, 2016). In the case of Hodgkin lymphomas, the bimodal distribution of incidence suggests that specific mechanisms are occurring in young patients, which have not been fully elucidated to date. Second, epidemiology has also proven a counter-intuitive association of lymphomas with immunosuppression, either inherited (common variable immunodepression for example) or acquired after HIV infection, or immunosuppressive drugs (van Leeuwen et al., 2009; Kaplan, 2012). This association revealed the role of the immune system in repressing the growth of transformed lymphocytes, either by active eradication of tumor cells or by exerting a competition for resources . Third, the analysis of the geographic distribution of lymphoma subtypes also shows striking differences, such as the higher incidence of T-cell lymphoma in Asia as compared to Western countries (Perry et al., 2016). These differences suggest two non-mutually exclusive hypotheses, related to environmental or genetic differences. The fourth major insight from epidemiological studies was to shed light on the role of pathogens such as Helicobacter pylori, HCV, EBV or HTLV1 in specific subtypes of lymphoma (Lecuit et al., 2004; Suarez et al., 2006; Couronné et al., 2018), which has been then confirmed experimentally. Besides pathogens, epidemiological studies have also demonstrated the role of environmental exposures such as herbicides in lymphomagenesis, which might have important consequences for health policies (Weisenburger, 2021). More recently, molecular epidemiology based on genome wide association studies have demonstrated the association of host genetic polymorphisms with the risk of specific lymphoma subtypes (Cerhan et al., 2014), highlighting unsuspected pathways which can then be experimentally explored"--
    MeSH term(s) Precision Medicine. ; Lymphoma/therapy. ; Signal Transduction.
    Keywords Cancer/Treatment
    Subject code 616.99406
    Language English
    Size 1 online resource (514 pages)
    Publisher John Wiley & Sons, Inc
    Publishing place Hoboken, New Jersey
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    ISBN 1-119-81995-4 ; 1-119-81993-8 ; 9781119819929 ; 978-1-119-81995-0 ; 978-1-119-81993-6 ; 111981992X
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  2. Article ; Online: Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.

    Ansell, Stephen M

    American journal of hematology

    2022  Volume 97, Issue 11, Page(s) 1478–1488

    Abstract: Disease overview: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8540 new patients annually and representing approximately 10% of all lymphomas in the United States.: Diagnosis: HL is composed of two distinct disease ... ...

    Abstract Disease overview: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8540 new patients annually and representing approximately 10% of all lymphomas in the United States.
    Diagnosis: HL is composed of two distinct disease entities: classical HL and nodular lymphocyte-predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich HL are subgroups of classical HL.
    Risk stratification: An accurate assessment of the stage of disease in patients with HL is critical for the selection of the appropriate therapy. Prognostic models that identify patients at low or high risk for recurrence, as well as the response to therapy as determined by positron emission tomography scan, are used to optimize therapy.
    Risk-adapted therapy: Initial therapy for HL patients is based on the histology of the disease, the anatomical stage, and the presence of poor prognostic features. Patients with early-stage disease are typically treated with combined modality strategies utilizing abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced-stage disease receive a longer course of chemotherapy, often without radiation therapy. However, newer agents, including brentuximab vedotin and anti-programmed death-1 (PD-1) antibodies, are now being incorporated into frontline therapy.
    Management of relapsed/refractory disease: High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. For patients who fail HDCT with ASCT, brentuximab vedotin, PD-1 blockade, non-myeloablative allogeneic transplant, or participation in a clinical trial should be considered.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Brentuximab Vedotin ; Disease Management ; Hodgkin Disease/diagnosis ; Hodgkin Disease/pathology ; Hodgkin Disease/therapy ; Humans ; Immunoconjugates ; Neoplasm Recurrence, Local ; Programmed Cell Death 1 Receptor
    Chemical Substances Immunoconjugates ; Programmed Cell Death 1 Receptor ; Brentuximab Vedotin (7XL5ISS668)
    Language English
    Publishing date 2022-09-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.26717
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Book: Rare hematological malignancies

    Ansell, Stephen M.

    (Cancer treatment and research ; 142)

    2008  

    Author's details Stephen M. Ansell, ed
    Series title Cancer treatment and research ; 142
    Collection
    Language English
    Size X, 432 S. : Ill., graph. Darst.
    Publisher Springer
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT015327877
    ISBN 978-0-387-73743-0 ; 9780387737447 ; 0-387-73743-X ; 0387737448
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  4. Article ; Online: PD-1 Blockade in Classic Hodgkin Lymphoma.

    Ansell, Stephen M

    JCO oncology practice

    2021  Volume 17, Issue 2, Page(s) 72–73

    MeSH term(s) B7-H1 Antigen ; Hodgkin Disease/drug therapy ; Humans ; Programmed Cell Death 1 Receptor ; Tumor Microenvironment
    Chemical Substances B7-H1 Antigen ; Programmed Cell Death 1 Receptor
    Language English
    Publishing date 2021-01-13
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 3028198-2
    ISSN 2688-1535 ; 2688-1527
    ISSN (online) 2688-1535
    ISSN 2688-1527
    DOI 10.1200/OP.20.01020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Fundamentals of immunology for understanding immunotherapy for lymphoma.

    Ansell, Stephen M

    Blood advances

    2021  Volume 4, Issue 22, Page(s) 5863–5867

    Abstract: An effective antitumor immune response in patients with lymphoma would eradicate the malignant B cells and cure the patient of the disease. This, however, does not occur, and a suboptimal antitumor response results in persistence and subsequent ... ...

    Abstract An effective antitumor immune response in patients with lymphoma would eradicate the malignant B cells and cure the patient of the disease. This, however, does not occur, and a suboptimal antitumor response results in persistence and subsequent progression of the patient's disease. The goals of immunotherapy are therefore to restore an effective antitumor immune response by promoting immune recognition, optimizing immune activation, and supporting persistence of the immune response resulting in subsequent immunological memory. Multiple mechanisms, however, are present within the tumor microenvironment that account for an inadequate immune response. These include loss of major histocompatibility complex expression on tumor cells and subsequent inadequate antigen presentation, increased expression of immunosuppressive ligands on malignant cells, populations of immune cells with suppressive function present in the tumor, and cytokines secreted by the malignant cell or other cells in the microenvironment that promote immune exhaustion or suppress the immune response. Successful immunotherapeutic strategies are specifically addressing these issues by promoting antigen presentation, improving recognition of the malignant cell, directly activating T cells and natural killer cells, and blocking immune checkpoint signaling that would suppress the immune response. Many of these approaches have proven highly successful in patients with various subtypes of lymphoma and are now being incorporated into standard clinical practice.
    MeSH term(s) Humans ; Immunologic Factors ; Immunotherapy ; Lymphoma/therapy ; Neoplasms ; Tumor Microenvironment
    Chemical Substances Immunologic Factors
    Language English
    Publishing date 2021-07-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2020002537
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Checkpoint Blockade in Lymphoma.

    Ansell, Stephen M

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2021  Volume 39, Issue 5, Page(s) 525–533

    MeSH term(s) Hodgkin Disease/drug therapy ; Hodgkin Disease/immunology ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Lymphoma/drug therapy ; Lymphoma/immunology
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2021-01-12
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.20.01522
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies.

    Bhardwaj, Vaishali / Ansell, Stephen M

    Frontiers in cell and developmental biology

    2023  Volume 11, Page(s) 1129343

    Abstract: Myeloid-derived suppressor cells (MDSCs) are pathologically activated neutrophils and monocytes that negatively regulate the immune response to cancer and chronic infections. Abnormal myelopoiesis and pathological activation of myeloid cells generate ... ...

    Abstract Myeloid-derived suppressor cells (MDSCs) are pathologically activated neutrophils and monocytes that negatively regulate the immune response to cancer and chronic infections. Abnormal myelopoiesis and pathological activation of myeloid cells generate this heterogeneous population of myeloid-derived suppressor cells. They are characterized by their distinct transcription, phenotypic, biochemical, and functional features. In the tumor microenvironment (TME), myeloid-derived suppressor cells represent an important class of immunosuppressive cells that correlate with tumor burden, stage, and a poor prognosis. Myeloid-derived suppressor cells exert a strong immunosuppressive effect on T-cells (and a broad range of other immune cells), by blocking lymphocyte homing, increasing production of reactive oxygen and nitrogen species, promoting secretion of various cytokines, chemokines, and immune regulatory molecules, stimulation of other immunosuppressive cells, depletion of various metabolites, and upregulation of immune checkpoint molecules. Additionally, the heterogeneity of myeloid-derived suppressor cells in cancer makes their identification challenging. Overall, they serve as a major obstacle for many cancer immunotherapies and targeting them could be a favorable strategy to improve the effectiveness of immunotherapeutic interventions. However, in hematological malignancies, particularly B-cell malignancies, the clinical outcomes of targeting these myeloid-derived suppressor cells is a field that is still to be explored. This review summarizes the complex biology of myeloid-derived suppressor cells with an emphasis on the immunosuppressive pathways used by myeloid-derived suppressor cells to modulate T-cell function in hematological malignancies. In addition, we describe the challenges, therapeutic strategies, and clinical relevance of targeting myeloid-derived suppressor cells in these diseases.
    Language English
    Publishing date 2023-04-05
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2737824-X
    ISSN 2296-634X
    ISSN 2296-634X
    DOI 10.3389/fcell.2023.1129343
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma.

    Chohan, Karan L / Ansell, Stephen M

    Clinical lymphoma, myeloma & leukemia

    2023  Volume 23, Issue 10, Page(s) 705–713

    Abstract: Classic Hodgkin lymphoma (HL) is a unique lymphoid malignancy where the malignant cells comprise only 1% to 2% of the total tumor cellularity. Over the past 2 decades, the treatment of HL has evolved drastically based on the advent of novel targeted ... ...

    Abstract Classic Hodgkin lymphoma (HL) is a unique lymphoid malignancy where the malignant cells comprise only 1% to 2% of the total tumor cellularity. Over the past 2 decades, the treatment of HL has evolved drastically based on the advent of novel targeted therapies. Novel agents including programmed death-1 (PD-1) inhibitors, antibody-drug conjugates such as brentuximab vedotin, bispecific antibodies, and chimeric antigen receptor (CAR) T cell therapies have served to shape the management of HL in the frontline as well as the relapsed and refractory (R/R) setting. Some of these agents have been incorporated into treatment algorithms, while others are currently under investigation demonstrating promising results. This review focuses on highlighting the underlying tumor biology forming the basis of therapeutics in HL, and reviews some of the emerging and established novel therapies.
    MeSH term(s) Humans ; Hodgkin Disease/pathology ; Brentuximab Vedotin/therapeutic use ; Immunoconjugates/therapeutic use ; Molecular Targeted Therapy/methods ; Biology
    Chemical Substances Brentuximab Vedotin (7XL5ISS668) ; Immunoconjugates
    Language English
    Publishing date 2023-06-14
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2023.06.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Book ; Online: Rare Hematological Malignancies

    Ansell, Stephen M.

    2008  

    Author's details edited by Stephen M. Ansell
    Keywords Hematology ; Oncology
    Language English
    Publisher Springer Science+Business Media, LLC
    Publishing place Boston, MA
    Document type Book ; Online
    HBZ-ID TT050386963
    ISBN 978-0-387-73743-0 ; 978-0-387-73744-7 ; 0-387-73743-X ; 0-387-73744-8
    DOI 10.1007/978-0-387-73744-7
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  10. Article ; Online: Fundamentals of immunology for understanding immunotherapy for lymphoma.

    Ansell, Stephen M

    Hematology. American Society of Hematology. Education Program

    2020  Volume 2020, Issue 1, Page(s) 585–589

    Abstract: An effective antitumor immune response in patients with lymphoma would eradicate the malignant B cells and cure the patient of the disease. This, however, does not occur, and a suboptimal antitumor response results in persistence and subsequent ... ...

    Abstract An effective antitumor immune response in patients with lymphoma would eradicate the malignant B cells and cure the patient of the disease. This, however, does not occur, and a suboptimal antitumor response results in persistence and subsequent progression of the patient's disease. The goals of immunotherapy are therefore to restore an effective antitumor immune response by promoting immune recognition, optimizing immune activation, and supporting persistence of the immune response resulting in subsequent immunological memory. Multiple mechanisms, however, are present within the tumor microenvironment that account for an inadequate immune response. These include loss of major histocompatibility complex expression on tumor cells and subsequent inadequate antigen presentation, increased expression of immunosuppressive ligands on malignant cells, populations of immune cells with suppressive function present in the tumor, and cytokines secreted by the malignant cell or other cells in the microenvironment that promote immune exhaustion or suppress the immune response. Successful immunotherapeutic strategies are specifically addressing these issues by promoting antigen presentation, improving recognition of the malignant cell, directly activating T cells and natural killer cells, and blocking immune checkpoint signaling that would suppress the immune response. Many of these approaches have proven highly successful in patients with various subtypes of lymphoma and are now being incorporated into standard clinical practice.
    MeSH term(s) Aged, 80 and over ; Cytokines/immunology ; Humans ; Immunotherapy ; Lymphocyte Activation ; Lymphoma, Large B-Cell, Diffuse/immunology ; Lymphoma, Large B-Cell, Diffuse/pathology ; Lymphoma, Large B-Cell, Diffuse/therapy ; Male ; T-Lymphocytes/immunology ; T-Lymphocytes/pathology ; Tumor Microenvironment/immunology
    Chemical Substances Cytokines
    Language English
    Publishing date 2020-12-04
    Publishing country United States
    Document type Case Reports ; Journal Article ; Review
    ZDB-ID 2084287-9
    ISSN 1520-4383 ; 1520-4391
    ISSN (online) 1520-4383
    ISSN 1520-4391
    DOI 10.1182/hematology.2020002537
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top